Breast Cancer Biomarker Predicts Efficacy of Chemo and Immunotherapy

A new study published in the Journal of Experimental & Clinical Cancer Research has identified the FGD3 protein as a promising predictive biomarker that potentially enhances the efficacy of chemotherapy and other cancer treatments that induce lytic cell death.

“We found, with all types of chemotherapy and all classes of breast cancer, there’s a very high correlation between the level of FGD3 and whether the patient responds favorably to chemotherapy,” said David J. Shapiro, PhD, professor of biochemistry at the University of Illinois Urbana-Champaign and senior author of the study. “Those with a high level are highly responsive; those with a low level are poorly responsive. This will allow us to identify those patients most likely to benefit from these kinds of cancer therapies.”